The EU recommends Merck COVID-19 pills for adults at risk of severe illness

European Union drug regulators administer Merck’s experimental COVID-19 pills on Friday within 5 days of initial symptoms to treat adults who do not require oxygen support and are at risk of exacerbating the disease. I advised you need to.

The European Medicines Agency (EMA) said that pills developed with Ridgeback Biotherapeutics should be taken twice daily for 5 days, but should be used during pregnancy for women planning to become pregnant. Not recommended.

“The EMA is to support national authorities who may determine the possibility of early use of the drug prior to marketing approval, given the increased infection and mortality rates of COVID-19 across the EU. I have issued this advice. “

Last month, EMA launched a rolling review of Merck’s tablet, Lagebrio, and on Friday examined data from Pfizer’s rival pills on its use before broader approval was obtained, as was the case with Merck. I started making recommendations.

Regulators on Friday also said that breastfeeding should be stopped before and after treatment with Merck’s Lagebrio.